Jump to ContentJump to Main Navigation
Show Summary Details

Cellular and Molecular Biology Letters

Editor-in-Chief: /


IMPACT FACTOR increased in 2015: 1.753

SCImago Journal Rank (SJR) 2015: 0.788
Source Normalized Impact per Paper (SNIP) 2015: 0.645
Impact per Publication (IPP) 2015: 1.748

Access brought to you by:

provisional account

Online
ISSN
1689-1392
See all formats and pricing



Select Volume and Issue

Natriuretic peptides in cardiovascular diseases

1Department of Anaesthesiology and Intensive Care Unit, Boleslaw Szarecki, University Hospital No. 5 in Łódź, Medical University in Łódź, Łódź, Poland

2Department Cardiology, 1st Chair of Cardiology and Cardiac Surgery, University Hospital No. 3 in Łódź, Medical University in Łódź, Łódź, Poland

3Department of Health Protection Policy, Medical University of Łódź, Łódź, Poland

42nd Department of Family Medicine, University Hospital No. 2 in Łódź, Medical University in Łódź, Łódź, Poland

5Department of Cardiology, Medical University of Łódź, Sterlinga 1/3, 91-425, Łódź, Poland

© 2007 University of Wrocław, Poland. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Cellular and Molecular Biology Letters. Volume 13, Issue 2, Pages 155–181, ISSN (Online) 1689-1392, DOI: 10.2478/s11658-007-0046-6, April 2008

Publication History

Published Online:
2008-04-09

Abstract

The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. The activities of natriuretic peptides and endothelins are strictly associated with each other. ANP and BNP inhibit endothelin-1 (ET-1) production. ET-1 stimulates natriuretic peptide synthesis. All natriuretic peptides are synthesized from polypeptide precursors. Changes in natriuretic peptides and endothelin release were observed in many cardiovascular diseases: e.g. chronic heart failure, left ventricular dysfunction and coronary artery disease.

Keywords: Atrial natriuretic peptide; Brain natriuretic peptide; C-type natriuretic peptide; Dendroaspis natriuretic peptide; Urodilatin; Endothelin-1

  • [1] de Bold, A.J., Borenstein, H.B., Veress, A.T. and Sonnenberg, A. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 28 (1981) 89–94. [CrossRef]

  • [2] Kangawa, K. and Matsuo, H. Purification and complete amino acid sequence of alfa-human atrial natriuretic polypeptide (alfa-hANP). Biochem. Biophys. Res. Commun. 118 (1984) 131–139. [CrossRef]

  • [3] Sudoh, T., Kangawa, K., Minamino, N. and Matsuo, H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78–81.

  • [4] Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., Ogawa, H., Okumura, K., Mukoyama, M. and Nakao, K. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195–203. [CrossRef]

  • [5] Barr, C.S., Rhodes, P. and Struthers, A.D. C-type natriuretic peptide. Peptides 17 (1996) 1243–1251. [CrossRef]

  • [6] de Lemos, J.A., McGuire, D.K. and Drazner, M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 361 (2003) 316–322.

  • [7] Komatsu, Y., Nakao, K., Suga, S., Ogawa, Y., Mukoyama, M., Arai, H., Shirakami, G., Hosoda, K., Nakagawa, O. and Hama, N. C-type natriuretic peptide in rats and humans. Endocrinology 129 (1991) 1104–1106. http://dx.doi.org/10.1210/endo-129-2-1104 [CrossRef]

  • [8] Stein, B.C. and Levin, R.I. Natriuretic peptides: Physiology, therapeutic potential and risk stratification in ischemic heart disease. Am. Heart J. 135 (1998) 914–923. [CrossRef]

  • [9] Schweitz, H., Vigne, P. and Minier, D. A new member of the natriuretic peptide family is present in the venom of green mamba (dendroaspis angusticeps) J. Biol. Chem. 267 (1992) 13928–13932.

  • [10] Schirger, J.A., Heublein, D.M., Chen, H.H., Lisy, O., Jougasaki, M., Wennberg, P.W. and Burnett, J.C. Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and ist increase during human heartbfailure. Mayo Clin. Proc. 74 (1999) 126–130. [CrossRef]

  • [11] Hickey, K.A., Rubanyi, G., Paul, R.J. and Higsmith, R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248 (1985) C550–C556.

  • [12] Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411–415.

  • [13] Ogawa, K., Oida, A., Sugimura, H., Kaneko, N., Nogi, N., Hasumi, M., Numao, T., Nagao, I. and Mori, S. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients-comparison of electrocardiography, chest radiography and echocardiography. Circ. J. 66 (2002) 122–126. [CrossRef]

  • [14] Cheung, B. and Kumana, C. Natriuretic peptides-relevance in cardiac disease. JAMA 280 (1998) 1983–1984. [CrossRef]

  • [15] Koskinas, K., Tzellos, T.G., Gougoulias, K., Gougoulias, G., Papakonstantinou, C. and Kouvelas, D. Simvastatin-induced rhabdomyolysis: a case study on clinical-decision making based on the evidence-based medicine approach. Arch. Med. Sci. 3 (2007) 267–271.

  • [16] Levin, E.R., Gardner, D.G. and Samson, W.K. Natriuretic peptides. N. Engl. J. Med. 339 (1998) 321–328.

  • [17] Kalra, P.R., Clague, J.R. and Bolger, A.P. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107 (2003) 571–573. [CrossRef]

  • [18] Grabowski, M., Malek, L.A., Karpinski, G, Filipiak, K.J. and Opolski, G. BNP in the differential diagnosis of amiodarone-induced pulmonary toxicity: a case report and review of the literature. Arch. Med. Sci. 2 (2006) 131–133.

  • [19] Banach, M., Markuszewski, L., Zasłonka, J., Grzegorczyk, J., Okoński, P. and Jegier, B. The role of inflammation in the pathogenesis of atherosclerosis. Przegl. Epidemiol. 58 (2004) 663–670.

  • [20] Piechota, M, Banach, M, Irzmański, R, Piechota-Urbańska, M, Kowalski, J. and Pawlicki, L. NT-proBNP levels correlate with organ failure in septic patients — preliminary report. Postepy Hig. Med. Dosw. (Online) 60 (2006) 632–636.

  • [21] Brown, A.M., Sease, K.L., Robey, J.L., Shofer, F.S. and Hollander, J.E. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann. Emerg. Med. 49 (2007) 153–163.

  • [22] Irzmański, R., Banach, M., Piechota, M., Barylski, M., Serwa-Stępień, E., Cierniewski, C., Jegier, B., Kowalski, J. and Pawlicki, L. BNP concentration in patients with mitral stenosis. Dependence on selected morphological parameters. Arch. Med. Sci. 2 (2006) 159–163.

  • [23] Brunner-La Rocca, H.P., Kiowski, W., Ramsay, D. and Sütsch, G. Therapeutic benefits of increasing natriuretic peptides levels. Cardiovasc. Res. 51 (2001) 510–520.

  • [24] Gutkowska, J., Antunes-Rodrigues, J. and McCann, S.M. Atrial natriuretic peptide in brain and pituitary gland. Physiol. Rev. 77 (1997) 465–515.

  • [25] Pidgeon, G.B., Richards, A.M. and Nichols, M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension 27 (1996) 906–913. [CrossRef]

  • [26] Irzmański, R., Banach, M., Piechota, M., Kowalski, J., Barylski, M., Cierniewski, C. and Pawlicki, L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin. Exp. Hypertens. 29 (2007) 149–164. [CrossRef]

  • [27] de Lemos, J.A. and Morrow, D.A. Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes. Am. Heart J. 153 (2007) 450–453. [CrossRef]

  • [28] Kowalski, J., Banach, M., Barylski, M., Irzmanski, R. and Pawlicki, L. Carvedilol modifies antioxidant status of patients with stable angina. Cell. Mol. Biol. Lett. 13 (2008) in press.

  • [29] Kapoun, A.M., Liang, F., O’Young, G., Damm, D.L., Quon, D., White, R.T., Munson, K., Lam, A., Schreiner, G.F. and Protter, A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factorbeta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453–461. [CrossRef]

  • [30] Dietz, J.R. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc. Res. 68 (2005) 8–17. [CrossRef]

  • [31] McDowell, G., Patterson, C., Maguire, S., Shaw, C., Nicholls, D.P. and Hall, C. Variability of Nt-proANP and C-ANP. Eur. J. Clin. Invest. 32 (2002) 545–548. [CrossRef]

  • [32] Witthaut, R., Busch, C., Fraunberger, P., Walli, A., Seidel, D., Pilz, G., Stuttmann, R., Speichermann, N., Verner, L. and Werdan, K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intens. Care Med. 29 (2003) 1696–1702. [CrossRef]

  • [33] Maisel, A.S., Clopton, P., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H., Steg, G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Bhalla, V., Herrmann, H.C., Aumont, M.C. and McCullough, P.A. BNP Multinational Study Investigators. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 147 (2004) 1078–1084. [CrossRef]

  • [34] Clerico, A., Lervasi, G. and Mariani, G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res. 31 (1999) 487–498. [CrossRef]

  • [35] Cosin Aguilar, J., Hernandiz Martinez, A., Diez Gil, J.L., Capdevila Carbonell, C., Salvador Sanz, A., Diago Torrent, J.L., Rivera Otero, M., Paya Serrano, R., Bertomeu Martinez, V., Sogorb Garri, F., Jordan Torrent, A., Mainar Latorre, L., Grau Jornet, G., Marti Llinares, S. and Miro Palau, V. Grupo de Estudio de la Disfuncion Ventricular Izquierda en la Comunidad. Value of NTproBNP concentration in an out-of-hospital adult population. Rev. Esp. Cardiol. 56 (2003) 236–244.

  • [36] Bozkurt, B. and Mann, D.L. Use of Biomarkers in the Management of Heart Failure. Are We There Yet? Circulation 107 (2003) 1231–233. [CrossRef]

  • [37] Irzmanski, R., Barylski, M., Banach, M., Piechota, M., Kowalski, J., Cierniewski, C. and Pawlicki, L. The concentration of atrial and brain natriuretic peptide in patients with idiopathic arterial hypertension. Med. Sci. Monit. 13 (2007) CR449–456.

  • [38] Rubanyi, G.M. and Polokoff, M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46 (1994) 325–415.

  • [39] Goto, K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull. 24 (2001) 1219–1230. [CrossRef]

  • [40] Benigni, A. and Remuzzi, G. Endothelin antagonists. Lancet 353 (1999) 133–138.

  • [41] Inoue, A., Yanagisawa, M., Kimura, S. Kasuya, Y., Miyauchi, T., Goto, K. and Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86 (1989) 2863–2867. [CrossRef]

  • [42] Ducancel, F. Endothelin-like peptides. Cell Mol. Life Sci. 62 (2005) 2828–2839. [CrossRef]

  • [43] Kedzierski, R.M. and Yanagisawa, M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 851–876. [CrossRef]

  • [44] Pawlowska, Z., Jerczynska, H., Szemraj, J., Baranska, P., Swiatkowska, M. and Cierniewski, C.S. Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol. Biol. Lett. 7 (2002) 1153–1157.

  • [45] Ohmnishi, M, Wada, A, Tsutamoto, T, Sawaki, M., Fujii, M., Matsumoto, T. and Kinoshita, M. Significant role of endothelin-A and endothelin-B receptor sin renal function in congestive heart failure. J. Cardiovasc. Pharmacol. 36 (5 Suppl.1) (2000) 44–49.

  • [46] Wang, J., Chiou, W.J., Gagne, G.D. and Wu-Wong, J.R. Internalization of type-A endothelin receptor. J. Cardiovasc. Pharmacol. 36 (5 Suppl.1) (2000) 61–65. [CrossRef]

  • [47] Iglarz, M. and Schiffrin, E.L. Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 5 (2003) 144–148. [CrossRef]

  • [48] Haynes, W.G., Ferro, C.J., O’Kane, K.P., Somerville, D., Lomax, C.C. and Webb, D.J. Systemic endothelin receptor blocade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93 (1996) 1860–1870. [CrossRef]

  • [49] Irzmański, R., Serwa-Stępień, E., Barylski, M., Banach, M., Kowalski, J. and Pawlicki, L. Endothelial dysfunction in hypertension. The role of natriuretic peptides and endothelin. Kardiol. Pol. 63 (Supl. 2) (2005) 457–461.

  • [50] Schiffrin, E.L., Intengan, H.D., Thibault, G. and Touyz, R.M. Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. 12 (1997) 354–367.

  • [51] Burrell, K.M., Molenaar, P., Dawson, P.J. and Kauman, A.J. Contractile and arrythmic effect of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J. Pharmacol. Exp. Ther. 292 (2000) 449–459.

  • [52] Saetrum Opgaard, O., Möller, S., de Vries, R., Edvinsson, L. and Saxena, P.R. Positive inotropic responses mediated by endothelin ET (A) and ET (B) receptors in human myocardial trabecule. Clin. Sci. (Lond.) 99 (2000) 161–168.

  • [53] Fabris, B., Chen, B., Pupic, V., Perich, R. and Johnston, C.I. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J. Cardiovasc. Pharmacol. 15 (Suppl. 2) (1990) 56–59.

  • [54] Weber, KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin. Nephrol. 17 (1997) 461–464.

  • [55] Benigni, A., Perico, G. and Remuzzi, G. Endothelin antagonists and renal protection. J. Cardiovasc. Pharmacol. 35 (4 Suppl. 2) (2000) 75–79. [CrossRef]

  • [56] Bassenge, E. Endothelial function in different organs. Prog. Cardiovasc. Dis. 39 (1996) 209–228. [CrossRef]

  • [57] Dries, D.L. Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Hypertension 49 (2007) 971–973. [CrossRef]

  • [58] Hama, N., Itoh, H., Shirakami, G., Nakagawa, O., Suga, S., Ogawa, Y., Masuda, I., Nakanishi, K., Yoshimasa, T. and Hashimoto, Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92 (1995) 1558–1564. [CrossRef]

  • [59] Peacock, W.F. The B-type natriuretic peptide assay: A rapid test for heart failure. Cleve. Clin. J. Med. 69 (2002) 243–251. [CrossRef]

  • [60] Qi, W., Mathisen, P., Kjekshus, J., Simonsen, S., Bjornerheim, R., Endresen, K. and Hall, C. Natriuretic peptides in patients aortic stenosis. Am. Heart J. 142 (2001) 725–732. [CrossRef]

  • [61] Nagaya, N., Nishikimi, T., Uematsu, M., Satoh, T., Kyotani, S., Sakamaki, F., Kakishita, M., Fukushima, K., Okano, Y., Nakanishi, N., Miyatake, K. and Kangawa, K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865–870. [CrossRef]

  • [62] Fagan, K.A., McMurtry, I.F. and Rodman, D.M. Role of endothelin-1 in lung disease. Respir. Res. 2 (2001) 90–101. [CrossRef]

  • [63] Teder, P. and Noble, P.W. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am. J. Respir. Cell Mol. Biol. 23 (2000) 19–26.

  • [64] Thomson, A.B., Keelan, M. and Thiesen, A. Small bowel review: normal physiology part 2. Dig. Dis. Sci. 46 (2001) 2588–2607. [CrossRef]

  • [65] Zuccarello, M. Endothelin: the “prime suspect” in cerebral vasospasm. Acta Neurochir. Suppl. 77 (2001) 61–65.

  • [66] Saito, Y., Nakao, K., Nishimura, K., Sugawara, A., Okumura, K., Obata, K., Sonoda, R., Ban, T., Yasue, H. and Amura, H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 76 (1987) 115–124. [CrossRef]

  • [67] Bonow, R.O. New insights into the cardiac natriuretic peptides. Circulation 93 (1996) 1946–1950. [CrossRef]

  • [68] Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Mabuchi, N., Hayashi, M., Ohnishi, M., Sawaki, M., Fujii, M., Horie, H., Sugimoto, Y. and Kinoshita, M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur. Heart J. 20 (1999) 1799–1807. [CrossRef]

  • [69] Maisel, A.S., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H., Clopton, P., Steg, P.G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Herrmann, H.C., McCullough, P.A. and the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347 (2002) 161–167. [CrossRef]

  • [70] Cosin Aguilar, J., Rodriguez Padial, L., Zamorano Gomez, J.L., Aristegui Urrestarazu, R., Armada Pelaez, B., Hernandiz Martinez, A., Aguilar Llopis, A. and Masramon Morell, X. Coronary risk differences in hypertensive patients of different autonomous communities. CORONARY study. Rev. Clin. Esp. 204 (2004) 614–625.

  • [71] McDonagh, T.A., Robb, S.D., Murdoch, D.R., Morton, J.J., Ford, I., Morrison, C.E., Tunstall-Pedoe, H., McMurray, J.J. and Dargie, H.J. Biochemical detection of left ventricular systolic dysfunction. Lancet 351 (1998) 9–13.

  • [72] Dao, Q., Krishnaswamy, P., Kazanegra, R., Harrison, A., Amirnovin, R., Lenert, L., Clopton, P., Alberto, J., Hlavin, P. and Maisel, A.S. Utility of Btype natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J. Am. Coll. Cardiol. 37 (2001) 379–385. [CrossRef]

  • [73] Cocco, G. and Chu, D. Weight reduction decreases NT-proBNP levels in obsese coronary patients with chronic diastolic heart failure. Arch. Med. Sci. 3 (2007) 112–116.

  • [74] Cowie, M.R., Struthers, A.D., Wood, D.A., Coats, A.J., Thompson, S.G., Poole-Wilson, P.A. and Sutton, GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349–1352.

  • [75] Berger, R., Huelsman, M., Strecker, K., Bojic, A., Moser, P., Stanek, B. and Pacher, R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392–2397. [CrossRef]

  • [76] Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Maeda, Y., Fukai, D., Ohnishi, M., Sugimoto, Y. and Kinoshita, M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509–516. [CrossRef]

  • [77] Collins, S.P., Ronan-Bentle, S. and Storrow, A.B. Diagnostic and prognostic usefulness of natriuretic peptides in Emergency Department patients with dyspnea. Ann. Emerg. Med. 41 (2003) 532–545. [CrossRef]

  • [78] Maisel, A.S., Koon, J., Krishnaswamy, P., Kazenegra, R., Clopton, P., Gardetto, N., Morrisey, R., Garcia, A., Chiu, A. and De Maria, A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am. Heart J. 141 (2001) 367–374. [CrossRef]

  • [79] Kimura, K., Yamaguchi, Y., Horii, M., Kawata, H., Yamamoto, H., Uemura, S. and Saito, Y. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 63 (2007) 699–702. [CrossRef]

  • [80] Cheng, V., Kazanagra, R., Garcia, A., Lenert, L., Krishnaswamy, P., Gardetto, N., Clopton, P. and Maisel, A. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J. Am. Coll. Cardiol. 37 (2001) 386–391. [CrossRef]

  • [81] Kawakami, R., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., Nakagawa, Y., Nakanishi, M., Tanimoto, K., Usami, S., Yasuno, S., Kinoshita, H., Chusho, H., Tamura, N., Ogawa, Y. and Nakao, K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110 (2004) 3306–3312. [CrossRef]

  • [82] Greig, D., Castro, P., Ferrada, M., Lim, J., Lopez, C., Braun, S., Cordova, S. and Salazar, M. Brain natriuretic peptide in primary pulmonary hypertension. Rev. Med. Chil. 134 (2006) 299–304.

  • [83] Piechota, M., Banach, M., Irzmanski, R., Barylski, M., Piechota-Urbanska, M., Kowalski, J. and Pawlicki, sL. Plasma endothelin-1 levels in septic patients. J. Intensive Care Med. 22 (2007) 232–239.

  • [84] Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T. and Kinoshita, M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J. 135 (1998) 823–832.

  • [85] Emdin, M., Passino, C., Prontera, C., Iervasi, A., Ripoli, A., Masini, S., Zucchelli, G.C. and Clerico, A. Cardiac natriuretic hormones, neuro hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin. Chem. Lab. Med. 42 (2004) 627–636

  • [86] McKinsey, T.A. and Nolson, E.N. Cardiac hypertrophy: sorting out the circuitry. Curr. Opin. Genet. Dev. 9 (1999) 267–274. [CrossRef]

  • [87] Piechota, M., Banach, M., Irzmański, R., Misztal, M., Rysz, J., Barylski, M., Piechota-Urbańska, M., Kowalski, J. and Pawlicki, L. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell. Mol. Biol. Lett. 12 (2007) 162–175.

  • [88] Gardner, R.S., Ozalp, F., Murday, A.J. Robb, S.D. and McDonagh, T.A. N-terminal brain natriuretic peptide: the new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24 (2003) 1735–1743. [CrossRef]

  • [89] Hodges, M., Bailey, J.J. and Church, T.R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 107 (2003) e13. [CrossRef]

  • [90] Hammerer-Lercher, A., Ludwig, W., Falkensammer, G., Muller, S., Neubauer, E., Puschendorf, B., Pachinger, O. and Mair, J. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 50 (2004) 1174–1183. [CrossRef]

  • [91] Clerico, A. and Emdin, M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin. Chem. 50 (2004) 33–50. [CrossRef]

  • [92] Remme, W.J. and Swedberg, K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22 (2001) 1527–1560. [CrossRef]

  • [93] Jourdain, P., Funck, F. and Bellorini, M. Brain natriuretic peptide and heart failure, from bench to bedside. Ann. Cardiol. Angeiol. (Paris) 53 (2004) 193–199.

  • [94] Anand, I.S., Fisher, L.D., Chiang, Y.T. Latini, R., Masson, S., Maggioni, A.P., Glazer, R.D., Tognoni, G., Cohn, J.N. and Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeFT. Circulation 107 (2003) 1278–1283. [CrossRef]

  • [95] Troughton, R.W., Frampton, C.M., Yandle, T.G. Espiner, E.A., Nicholls, M.G. and Richards, A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126–1130.

  • [96] Brunner-La Roca, H.P., Kaye, D.M., Woods, R.L. Hastings, J. and Esler, M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared to control subjects. J. Am. Coll. Cardiol. 37 (2001) 1221–1227. [CrossRef]

  • [97] Abraham, W.T., Lowes, B.D., Ferguson, D.A., Odom, J., Kim, J.K., Robertson, A.D., Bristow, M.R. and Schrier, RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with advanced hemodynamically decompensated heart failure. J. Card. Fail. 4 (1998) 37–44. [CrossRef]

  • [98] Tepper, D. Frontiers in congestive heart failure: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. Congest. Heart Fail. 7 (2001) 330.

  • [99] Banach, M., Goch, A., Misztal, M., Rysz, J., Barylski, M., Jaszewski, R. and Goch, J.H.. Low output syndrome following aortic valve replacement. Predictors and prognosis. Arch. Med. Sci. 3 (2007) 117–122.

  • [100] Banach, M., Drożdż, J., Okoński, P. and Rysz, J. Immunological aspects of the statins’ function in patients with heart failure. A raport from the Annual Conference of ESC — Heart Failure 2005. Cell. Mol. Immunol. 2 (2005) 433–437.

  • [101] Irzmański, R., Piechota, M., Barylski, M., Banach, M., Kowalski, J., Serwa-Stępień, E., Drożdż, J. and Pawlicki, L. NT-proBNP in patients after acute coronary syndrome with ST segment elevation subjected to early posthospitalization cardiologic rehabilitation. Arch. Med. Sci. 2 (2006) 262–267.

  • [102] Sabatine, M.S., Morrow, D.A., de Lemos, J.A., Omland, T., Desai, M.Y., Tanasijevic, M., Hall, C., McCabe, C.H. and Braunwald, E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J. Am. Coll. Cardiol. 44 (2004) 1988–1995. [CrossRef]

  • [103] James, S.K., Lindahl, B., Siegbahn, A., Stridsberg, M., Venge, P., Armstrong, P., Barnathan, E.S., Califf, R., Topol, E.J., Simoons, M.L. and Wallentin, L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275–281.

  • [104] de Lemos, J.A., Morrow, D.A., Bentley, J.H., Omland, T., Sabatine, M.S., McCabe, C.H., Hall, C., Cannon, C.P. and Braunwald, E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345 (2001) 1014–1021. [CrossRef]

  • [105] Bassan, R., Potsch, A., Maisel, A., Tura, B., Villacorta, H., Nogueira, M.V., Campos, A., Gamarski, R., Masetto, A.C. and Moutinho, M.A. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur. Heart J. 26 (2005) 234–240.

  • [106] Jarai, R., Iordanova, N., Jarai, R., Raffetseder, A., Woloszczuk, W., Gyöngyösi, M., Geyer, G., Wojta, J. and Huber K. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal proatrial natriuretic peptide. Eur. Heart J. 26 (2005) 250–256.

  • [107] Skrzypiec, M. and Spring, A. Plasma levels of atrial (ANP) and brain (BNP) natriuretic peptides in patients with unstable angina pectoris. Mag. Lek. Rodz. 12 (2004) (http://www.medicus.com.pl/lr/lr_arch_2004-12.html)

  • [108] Schnabel, R., Rupprecht, H.J., Lackner, K.J., Lubos, E., Bickel, C., Meyer, J., Münzel, T., Cambien, F., Tiret, L. and Blankenberg, S.; AtheroGene Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur. Heart J. 26 (2005) 241–249.

  • [109] Kowalski, J., Banach, M., Barylski, M., Grycewicz, J., Irzmanski, R. and Pawlicki, L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J. Cardiovasc. Pharmacol. 48 (2006) 143–147. [CrossRef]

  • [110] Heusch, P., Skyschally, A., Leineweber, K., Haude, M., Erbel, R. and Heusch, G. The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha. Arch. Med. Sci. 3 (2007) 83–92.

  • [111] Piechota, M., Irzmański, R., Banach, M., Kowalski, J. and Pawlicki, L. Impedance cardiography in haemodynamic monitoring of septic patients: a prospective study. Arch. Med. Sci. 3 (2007) 145–151.

  • [112] Schnabel, R., Lubos, E., Rupprecht, H.J., Espinola-Klein, C., Bickel, C., Lackner, K.J., Cambien, F., Tiret, L., Munzel, T. and Blankenberg, S. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina. results from the AtheroGene Study. J. Am. Coll. Cardiol. 47 (2006) 552–558. [CrossRef]

  • [113] Omland, T., Persson, A., Ng, L., O’Brien, R., Karlsson, T., Herlitz, J., Hartford, M. and Caidahl, K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913–2918. [CrossRef]

  • [114] Schaller, B.J. The role of endothelin in stroke: Experimental data and underlying pathophysiology. Arch. Med. Sci. 2 (2006) 146–158.

  • [115] Pidgeon, G.B., Richards, A.M. and Nichols, M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension 27 (1996) 906–913. [CrossRef]

  • [116] Gryglewski, R.J. Interactions between endothelial mediators. Pharmacol. Toxicol. 77 (1995) 1–9. [CrossRef]

  • [117] Ferro, C.J. and Webb, D.J. Endothelial dysfunction and hypertension. Drugs 53 (Suppl. 1) 30–41.

  • [118] Castillo J.R., Zagler, A., Carrillo-Jimenez, R. and Hennekens, C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int. J. Infect. Dis. 8 (2004) 271–274. [CrossRef]

  • [119] Charpentier, J., Luyt, C.E., Fulla, Y., Vinsonneau, C., Cariou, A., Grabar, S., Dhainaut, J.F., Mira, J.P. and Chiche, J.D. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 32 (2004) 660–665. [CrossRef]

  • [120] Witthaut, R. Science review: natriuretic peptides in critical illness. Crit. Care 8 (2004) 342–349. [CrossRef]

  • [121] Chua, G. and Kang-Hoe, L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit. Care 8 (2004) 248–250. [CrossRef]

  • [122] Kato, N., Sugiyama, T., Morita, H., Nabika, T., Kurihara, H., Yamori, Y. and Yazaki, Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin. Sci. (London) 98 (2000) 251–258.

  • [123] Rubattu, S., Giliberti, R., Ganten, U. and Volpe, M. A differential brain atrial natriuretic peptide expression co-segregates with occurrence of early stroke in the stroke prone phenotype of spontaneously hypertensive rat. J. Hypertens. 17 (1999) 1849–1852. [CrossRef]

  • [124] Gruchala, M, Ciecwierz, D, Wasag, B, Targonski, R., Dubaniewicz, W., Nowak, A., Sobiczewski, W., Ochman, K., Romanowski, P., Limon, J. and Rynkiewicz, A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J. 145 (2003) 125–131. [CrossRef]

  • [125] Nakayama, T., Soma, M., Saito, S., Honye, J., Sato, M., Aoi, N., Kosuge, K., Haketa, A., Kanmatsuse, K. and Kokubun, S. Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med. Sci. Monit. 9 (2003) CR505–CR510.

  • [126] Tiret, L., Mallet, C., Poirier, O., Nicaud, V., Millaire, A., Bouhour, J.B., Roizes, G., Desnos, M., Dorent, R., Schwartz, K., Cambien, F. and Komajda, M. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J. Am. Coll. Cardiol. 35 (2000) 29–35. [CrossRef]

  • [127] Ono, K., Mannami, T., Baba, S., Yasui, N., Ogihara, T. and Iwai, N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens. Res. 25 (2002) 727–730. [CrossRef]

  • [128] Irzmański, R., Piechota, M., Barylski, M., Banach, M., Gławęda, B., Kowalski, J., Cierniewski, C., Kośmider, M. and Pawlicki, L. Dynamics of changes of the BNP concentration in patients with stable angina pectoris qualified for PTCA. Dependence on the selected morphological and haemodynamic parameters. Arch. Med. Sci. 2 (2006) 15–19.

  • [129] Topol, E.J. Nesiritide — not verified. N. Engl. J. Med. 353 (2005) 113–116. [CrossRef]

  • [130] Sackner-Bernstein, J.D., Skopicki, H.A. and Aaronson, K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487–1491. [CrossRef]

  • [131] Sackner-Bernstein, J.D., Kowalski, M., Fox, M. and Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900–1905.

  • [132] Meyer, M., Pfarr, E., Schirmer, G., Uberbacher, H.J., Schope, K., Bohm, E., Fluge, T., Mentz, P., Scigalla, P. and Forssmann, W.G. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. 21 (1999) 85–100. http://dx.doi.org/10.3109/08860229909066972 [CrossRef]

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Aleksander Goch, Maciej Banach, Dimitri P. Mikhailidis, Jacek Rysz, and Jan Henryk Goch
Clinical and Experimental Hypertension, 2009, Volume 31, Number 1, Page 20
[2]
Amirhossein Sahebkar, Kazuhiko Kotani, Corina Serban, Sorin Ursoniu, Dimitri P. Mikhailidis, Steven R. Jones, Kausik K. Ray, Michael J. Blaha, Jacek Rysz, Peter P. Toth, Paul Muntner, Gregory Y.H. Lip, and Maciej Banach
Atherosclerosis, 2015, Volume 241, Number 2, Page 433
[3]
Agata Bielecka-Dabrowa, Stephan von Haehling, Wilbert S. Aronow, Mustafa I. Ahmed, Jacek Rysz, and Maciej Banach
International Journal of Cardiology, 2013, Volume 168, Number 3, Page 2404
[4]
Mehmet Kemal Tur, Benjamin Etschmann, Alexander Benz, Ellen Leich, Christiane Waller, Kai Schuh, Andreas Rosenwald, Georg Ertl, Anne Kienitz, Andre T. Haaf, Andreas Bräuninger, and Stefan Gattenlöhner
The American Journal of Pathology, 2013, Volume 182, Number 4, Page 1205
[5]
Alyaa A Kotby, Khaled H Taman, Heba Tallah A Sedky, Nevin MM Habeeb, Eman S El-Hadidi, and Hanan S Yosseif
Journal of Paediatrics and Child Health, 2013, Volume 49, Number 1, Page 43
[6]
Kara Osterbur, Do-Hyeon Yu, and Amy E. DeClue
Research in Veterinary Science, 2013, Volume 94, Number 3, Page 478
[7]
Juan José Badimón, Carlos G. Santos-Gallego, Francisco Torres, Jesús Castillo, and Juan Carlos Kaski
Revista Española de Cardiología Suplementos, 2011, Volume 11, Page 21
[8]
Camilla Calvieri, Speranza Rubattu, and Massimo Volpe
Journal of Molecular Medicine, 2012, Volume 90, Number 1, Page 5
[9]
Soo Mi Kim, Yoon Ah Kim, Sun Young Kim, Suhn Hee Kim, Kyung Woo Cho, and Sung Zoo Kim
Regulatory Peptides, 2011, Volume 167, Number 1, Page 42
[10]
Boubacar Pasto Wann, Marie-Claude Audet, and Hymie Anisman
Hormones and Behavior, 2010, Volume 58, Number 5, Page 907
[11]
Juan José Badimón, Carlos G. Santos-Gallego, Francisco Torres, Jesús Castillo, and Juan Carlos Kaski
Revista Española de Cardiología Suplementos, 2011, Volume 11, Page 21
[12]
M Banach, F M Casares, R M Kream, A Gluba, J Rysz, and G B Stefano
Journal of Human Hypertension, 2010, Volume 24, Number 11, Page 713
[13]
M. Kowalczyk, M. Banach, G. Y. H. Lip, D. Kozłowski, D. P. Mikhailidis, and J. Rysz
International Journal of Clinical Practice, 2010, Volume 64, Number 8, Page 1148

Comments (0)

Please log in or register to comment.